ArticleESMO open2024
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
Article in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 5 citations in OpenAlex.
- Clinical implementation of intensity modulated proton therapy in breath-hold for mediastinal lymphoma patients using surface monitoring and nasal high-flow therapy.Physics and imaging in radiation oncology · 2026Article
- Spatial tissue analysis of secondary sarcoma following CAR T cell therapy for B cell lymphoma.iScience · 2026Article
- Causes of excess nonlymphoma death in 58 000 patients with DLBCL diagnosed during 1997 to 2020 and followed for up to 25 years.Blood advances · 2026Article
- Improved organs-of-interest dose reduction potential with intensity modulated proton therapy and breath-hold in mediastinal lymphoma.Physics and imaging in radiation oncology · 2026Article
- Article
- Metachronous EBV-positive classical Hodgkin lymphoma following EBV-positive diffuse large B-cell lymphoma: a case report and literature review.Frontiers in oncology · 2026Article
- Article
- Second Cancer Incidence and Cause-Specific Mortality in Primary Gastrointestinal Non-Hodgkin Lymphoma Survivors: A Population-Based Cohort Study.Cancer medicine · 2025Article
- The onset characteristics and prognosis of patients with radiation-associated second primary malignancy: a pancancer study in the US SEER cancer registries.Translational cancer research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 20 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe introduction of rituximab significantly improved the prognosis of diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of evaluating the long-term consequences of exposure to radiotherapy, alkylating agents and anthracycline-containing (immuno)chemotherapy among DLBCL survivors.
methodsLong-term risk of subsequent malignant neoplasms (SMNs) was examined in a multicenter cohort comprising 2373 5-year DLBCL survivors treated at ages 15-61 years in 1989-2012. Observed SMN numbers were compared with expected cancer incidence to estimate standardized incidence ratios (SIRs) and absolute excess risks (AERs/10 000 person-years). Treatment-specific risks were assessed using multivariable Cox regression.
resultsAfter a median follow-up of 13.8 years, 321 survivors developed one or more SMNs (SIR 1.5, 95% CI 1.3-1.8, AER 51.8). SIRs remained increased for at least 20 years after first-line treatment (SIR ≥20-year follow-up 1.5, 95% CI 1.0-2.2, AER 81.8) and were highest among patients ≤40 years at first DLBCL treatment (SIR 2.7, 95% CI 2.0-3.5). Lung (SIR 2.0, 95% CI 1.5-2.7, AER 13.4) and gastrointestinal cancers (SIR 1.5, 95% CI 1.2-2.0, AER 11.8) accounted for the largest excess risks. Treatment with >4500 mg/m
conclusionFive-year DLBCL survivors have an increased risk of SMNs. Risks were higher for survivors ≤40 years at first treatment and survivors treated with >4500 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.